0000000000449701

AUTHOR

T Lotti

showing 3 related works from this author

Nota Introduttiva

2012

Dermopatie tecnopatie affezioni sistemicheSettore MED/44 - Medicina Del Lavoro
researchProduct

Efficacy and safety of Cyprofloxacin XR 1000mg once daily versus Ciprofloxacin 500mg twice daily in the treatment of complicated urinary tract infect…

2009

The aim of this trial was to compare the efficacy and safety of extended-release ciprofloxacin (CIPRO XR) versus the immediate-release formulation (CIPRO IR) in the treatment of complicated urinary tract infections (UTIs). 212 patients were randomized to CIPRO XR 1,000 mg tablet once daily or CIPROXIN IR 500 mg tablet twice daily. Treatment efficacy was evaluated by bacteriological outcome. Safety was measured by recording adverse events. The rate of bacteriological eradication was 83% in the CIPRO XR group and 75% in the CIPRO IR. the overall incidence of adverse events reported was higher in the CIPRO IR group. The authors conclude that CIPRO XR is a safe and effective treatment for compl…

cUTI ciprofloxacin XR ciprofloxacin iR antibiotics urinary tract infectionSettore MED/24 - Urologia
researchProduct

Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

2015

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in…

RegistrieMaletaiwanAntitubercular AgentsBiological Factorquantiferon-tb-goldAntitubercular AgentBiological FactorsexperienceResidence Characteristics80 and overPrevalenceRegistriesYoung adultriskAged 80 and overLatent TuberculosiLatent tuberculosispsoriasisMiddle AgedItalyFemaletubercolosistubercolosiAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young Adult; 2708Humanmedicine.drugAdultmedicine.medical_specialtyAdolescentchronic plaque psoriasisTuberculinconsensus statementtubercolosis; psoriasisDermatology.Young Adulttuberculosis infectionSettore MED/35Age DistributionLatent TuberculosisInternal medicinePsoriasismedicineAdalimumabfactor antagonistsHumansPsoriasisnecrosis-factor blockers; quantiferon-tb-gold; consensus statement; factor antagonists; systemic treatment; therapy; experience;taiwan; assay; risknecrosis-factor blockersSex DistributionAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Antitubercular Agents; Biological Factors; Chronic Disease; Female; Humans; Italy; Latent Tuberculosis; Male; Middle Aged; PUVA Therapy; Prevalence; Psoriasis; Registries; Residence Characteristics; Sex Distribution; Tuberculin Test; Young AdultPUVA TherapyAgedPsoriasiHistory of tuberculosistherapytuberculosis infection chronic plaque psoriasisItalian Psocare Registrybusiness.industryTuberculin TestOdds ratiosystemic treatmentassaymedicine.diseasebacterial infections and mycosesConfidence intervalSurgeryResidence CharacteristicChronic DiseaseItalian Psocare Registrybusiness2708
researchProduct